Toshifumi Yokota, the study’s principal investigator, published his findings Aug. 6 in the peer-reviewed journal, Proceedings of the National Academy of Sciences. He is a researcher in the Department of Medical Genetics and holds two research chairs: The Friends of Garrett Cumming Research Chair, Muscular Dystrophy Canada; and the H.M. Toupin Neurological Science Chair.
Yokota has worked on this research for more than five years. He is now using the same drug cocktail on human cells with Duchenne muscular dystrophy and hopes to see similar results.
Duchenne muscular dystrophy, one of the most common genetic disorders, is caused by a lack of dystrophin, a muscle-supporting protein. In the lab, the drug cocktail improved normal functioning of the mutated gene that triggers the condition. The therapy allowed the lab models to produce 10 per cent to 15 per cent normal levels of dystrophin.
“With this drug cocktail, we were able to target the hot-spot mutated parts of the gene,” said Yokota. “The results were very good—better than we expected. The Duchenne muscular dystrophy condition was less severe.”
Yokota noted that about half of those living with Duchenne could potentially benefit from the drug cocktail, once further testing is conducted and clinical trials are completed.
He worked with colleagues in the United States and Japan on the findings.
The organizations that funded the research include the Neurological and Psychiatric Disorders of the National Center of Neurology and Psychiatry; the Ministry of Health, Labour and Welfare of Japan; the Foundation to Eradicate Duchenne; the U.S. Department of Defense; the National Institutes of Health; the Muscular Dystrophy Association; The Friends of Garrett Cumming Research; H.M. Toupin Neurological Science Research and Muscular Dystrophy Canada.
University of Alberta